top of page
Search

Should You Power Through LDN Side Effects? Why the Answer Is Almost Always No



Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com


Disclaimer: This blog post is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Low dose naltrexone (LDN) is used off-label for essentially all of the conditions discussed below; it is not FDA-approved for any of them. Always consult with a qualified clinician before starting, adjusting, or discontinuing any medication. Individual responses to LDN vary considerably.



One of the questions I hear most often in my practice is this: If I develop significant side effects from LDN, should I power through them?


My answer depends on the level of side effect — but when they are significant, the answer is almost always no.

When Rapid Titration Outpaces the Body's Capacity

I recently worked with a patient who increased their dose very rapidly. The initial steps went smoothly — from 1 microgram (0.001 mg) to 5 micrograms (0.005 mg), no problems. But from there, the jumps to 10 and then 20 micrograms triggered significant side effects.


This is not an unusual pattern. Individuals who are doing well at the lowest doses can be tempted — or advised — to move quickly toward higher targets. But the pace of titration matters at least as much as the destination dose. Side effects during a dose increase are not a signal to push harder; they are a signal that the increase was either too fast or too large for that person's system at that time.


This pattern — tolerating very low doses well but encountering problems with larger jumps — is one of the most common and most avoidable sources of difficulty in LDN therapy.[1],[2]

Why "Powering Through" Can Be the Wrong Move

There is a common assumption, sometimes reinforced in online communities, that LDN side effects are just something to tolerate until the body adjusts. In some cases that is true — mild, transient vivid dreams or brief sleep disruption during the first one to two weeks often resolve without any change in dose.[3],[4]


But when side effects are significant — meaning they interfere meaningfully with sleep, function, energy, mood, or quality of life — my standard recommendation is straightforward: stop the LDN.


This is not a failure of the medication or of the patient. It is the safest way to reset the system, gather information, and plan a more careful approach.

The Recovery Period: What It Involves and How Long It Takes

Once LDN has been stopped, the next step is allowing the body enough time to recover before any restart is considered. In my clinical experience, this recovery window can range considerably depending on the individual:


  • 3 to 7 days for mild-to-moderate reactions in otherwise non-sensitive individuals

  • 7 to 14 days for more pronounced symptoms or moderately sensitive individuals

  • 14 to 30 days for those with significant sensitivity syndromes, such as MCAS, ME/CFS, or conditions involving heightened nervous system reactivity


The rationale for this recovery period involves several overlapping systems. The traditional proposed mechanism of LDN centers on a brief, partial blockade of opioid receptors followed by a compensatory upregulation of endogenous opioid production and receptor density — what some refer to as the "endorphin rebound."[5],[6] If a patient experiences significant adverse effects, the theory suggests that the opioid receptor system and related endorphin signaling need time to re-equilibrate before naltrexone is reintroduced.


Editor's note on the endorphin rebound hypothesis: The concept that LDN's primary benefit derives from endorphin upregulation is widely cited, but the evidence is more nuanced than the popular narrative suggests. A 2021 study by Metz, Daimon, and Hentges in eNeuro examined whether LDN alters the activity of proopiomelanocortin (POMC) neurons in mice — the hypothalamic neurons responsible for producing β-endorphin — and found no evidence that LDN changed opioid receptor sensitivity on POMC neurons, Pomc mRNA production, or plasma β-endorphin levels.[7] The authors concluded that LDN's reported benefits appear to be independent of the POMC/β-endorphin pathway. This does not invalidate the clinical observation that a recovery period is needed after significant side effects. It does suggest that what is "recovering" may involve broader opioid receptor re-equilibration, glial and neuroinflammatory system resettling, or nervous system recalibration rather than a simple endorphin deficit. Animal data clearly show that naltrexone administration leads to robust mu-opioid receptor upregulation — increasing receptor density by as much as 93% — with gradual normalization over subsequent days.[8],[9] That receptor-level normalization, combined with the nervous system's broader adaptive response, likely contributes to the clinically observed need for a washout period before safe reinitiation.


The honest summary: the recovery period is clinically real and well-supported by practice experience. The precise mechanism driving it is less settled than many accounts imply, and attributing it solely to "endorphin deficiency" oversimplifies the biology.

Restarting Requires Expert Guidance

After the recovery period, the patient should not simply resume at the same dose that caused difficulty. The appropriate restart strategy depends on the full clinical picture — what the side effect was, how severe it was, how sensitive the person's system has shown itself to be, and what underlying conditions are in play.


In many cases, restarting at a substantially lower dose and titrating more slowly is sufficient. For highly sensitive individuals, the restart dose may need to be in the low microgram range — sometimes even lower — before any upward movement is attempted.[10] The specific dosing tiers (microgram, nanogram, and in rare cases picogram) and the pharmacologic rationale for them are discussed in greater detail in the companion post LDN Primer Follow-Up: What to Do When LDN Causes Side Effects.


This is precisely the kind of decision that should be made in partnership with a clinician experienced in LDN titration across the full dosing spectrum — not self-directed based on another person's experience or a standardized protocol.

The Value of Expert Guidance in LDN Therapy

LDN is a powerful tool, but it is not a simple one. The difference between a productive LDN experience and a difficult one often comes down to the titration strategy — how quickly the dose is advanced, how side effects are interpreted, whether the clinician has the experience to recognize when a pause, a step back, or a reformulation is needed.


If you have had to stop LDN because of side effects, that is not the end of the road. But the path forward should be individualized, informed by your specific response pattern, and guided by someone who understands the pharmacology and clinical nuance of this medication.




Summary

Step

Action

Side effects emerge

Assess severity. Mild and transient symptoms (vivid dreams, brief sleep disruption) may resolve on their own within 1–2 weeks.

Significant side effects

Stop LDN. Do not attempt to push through symptoms that meaningfully impair function, sleep, or quality of life.

Recovery period

Allow the system to settle — typically 3 to 30 days depending on individual sensitivity and the severity of the reaction.

Restart planning

Work with an LDN-experienced clinician to determine the appropriate restart dose and titration schedule. The restart dose may be substantially lower than the dose that caused difficulty.








References

  1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250


  1. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320 (Sleep disturbance was the single most common side effect.)


  1. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310


  1. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938


  1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. (Proposed mechanism includes temporary receptor blockade followed by compensatory endorphin upregulation and increased receptor density.) PMID: 24526250


  1. Kim YH. Endorphins: Biochemistry, Bioregulation, and Clinical Levers. Integrative Functional Medicine and LDN Community (ifmsynergy.com). Published July 16, 2026. https://www.ifmsynergy.com/endorphins-biochemistry-bioregulation-and-clinical-levers/


  1. Metz MJ, Daimon CM, Hentges ST. Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and β-endorphin. eNeuro. 2021;8(3):ENEURO.0087-21.2021. doi:10.1523/ENEURO.0087-21.2021. PMID: 34031099


  1. Lesscher HMB, Bailey A, Burbach JP, van Ree JM, Kitchen I, Gerrits MAFM. Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci. 2003;17(5):1006–1012. doi:10.1046/j.1460-9568.2003.02538.x. PMID: 12653976


  1. Tempel A, Gardner EL, Zukin RS. Opioid antagonist modulation: naltrexone-induced receptor upregulation. Eur J Pharmacol. 1984;106(1):101–106. doi:10.1016/0014-2999(84)90683-9. PMID: 6152212 (Naltrexone treatment increased opioid receptor density by up to 93%, normalizing over subsequent days.)


  1. Kim YH. LDN Primer Follow-Up: What to Do When LDN Causes Side Effects. Integrative Functional Medicine and LDN Community (ifmsynergy.com). Published July 14, 2026. https://www.ifmsynergy.com/ldn-primer-follow-up-what-to-do-when-ldn-causes-side-effects/




Related Reading




About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience spanning preventive medicine, integrative and functional medicine, medical acupuncture, and integrative holistic medicine. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness.


He is the author of three books and more than 20 published articles in integrative medicine.



 
 
 

Comments

bottom of page